Golimumab

Golimumab^?
Therapeutic monoclonal antibody
Source	Human
Target	TNFα
Identifiers
CAS number	476181-74-5
ATC code	?
PubChem	?
Chemical data
Formula	C₆₅₃₀H₁₀₀₆₈N₁₇₅₂O₂₀₂₆S₄₄
Mol. mass	?
Pharmacokinetic data
Bioavailability	?
Metabolism	?
Half life	?
Excretion	?
Therapeutic considerations
Pregnancy cat.	?
Legal status
Routes	?

Golimumab (CNTO 148) is a human monoclonal antibody which is used as an immunosuppressive drug. Golimumab targets tumor necrosis factor alpha (TNF-alpha), a pro-inflammatory molecule.

Golimumab was developed by Centocor and is being tested as a subcutaneous injection in phase III clinical trials for treatment of rheumatoid arthritis and will be marketed by Schering-Plough in Europe.^{[citation needed]} Johnson & Johnson, the parent company of Centocor, has requested approval from European Medicines Agency for the use of golimumab as a treatment for rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.^[1]

[edit] References

v • d • e Immunomodulators - Immunosuppressants - Immunosuppressive drugs (L04)

Monoclonal antibodies	TNF inhibitors (Infliximab, Adalimumab, Certolizumab pegol), Afelimomab, Aselizumab, Atlizumab, Atorolimumab, Basiliximab, Belimumab, Bertilimumab, Cedelizumab, Clenoliximab, Daclizumab, Dorlimomab aritox, Dorlixizumab, Eculizumab, Efalizumab, Elsilimomab, Erlizumab, Faralimomab, Fontolizumab, Galiximab, Gantenerumab, Gavilimomab, Golimumab, Gomiliximab, Ibalizumab, Inolimomab, Ipilimumab, Keliximab, Lebrilizumab, Lerdelimumab, Lumiliximab, Maslimomab, Mepolizumab, Metelimumab, Morolimumab, Muromonab-CD3, Natalizumab, Nerelimomab, Ocrelizumab, Odulimomab, Omalizumab, Otelixizumab, Pascolizumab, Pexelizumab, Reslizumab, Rovelizumab, Ruplizumab, Siplizumab, Talizumab, Telimomab aritox, Teneliximab, Teplizumab, Tocilizumab, Toralizumab, Vapaliximab, Vepalimomab, Visilizumab, Zanolimumab, Ziralimumab, Zolimomab aritox

-imus	Abetimus, Deforolimus, Everolimus, Gusperimus, Pimecrolimus, Sirolimus, Tacrolimus, Temsirolimus, Zotarolimus

-cept (Fusion protein)	Abatacept, Aflibercept, Alefacept, Belatacept, Rilonacept, TNF inhibitor (Etanercept)

Other	Anakinra, Azathioprine, Ciclosporin, Leflunomide, Methotrexate, Mycophenolic acid, Thalidomide

v • d • e Human monoclonal antibodies ("-u-")

"-limu-" (immune system)	immunosuppression: Adalimumab, Atorolimumab, Gantenerumab, Golimumab, Lerdelimumab, Metelimumab, Morolimumab, Ziralimumab immune activation: Ipilimumab, Tremelimumab other: Bertilimumab

"-kinu-" (interleukin as target)	Canakinumab

"-tumu-" (cancer immunotherapy)	Adecatumumab, Anetumumab, Belimumab, Duntumumab, Iratumumab, Lexatumumab, Lucatumumab, Mapatumumab, Ofatumumab, Panitumumab, Pritumumab, Votumumab, Zalutumumab, Zanolimumab

"-osu-" (bone)	Denosumab

"-mulu-" (musculoskeletal)	Durimulumab, Durmulumab, Stamulumab

"-fungu-" (fungal)	Efungumab

"-viru-" (viral)	Exbivirumab, Libivirumab, Regavirumab, Sevirumab, Tuvirumab

"-bacu-" (bacterial)	Nebacumab, Raxibacumab